CD274 and prostate cancer: Prostate cancer employs multiple evasion strategies, including the downregulation of major histocompatibility complex class I, impaired antigen processing (TAP1/2 deficiencies), and the upregulation of immune checkpoints (PD-L1, B7-H3, and VISTA).